LAURA PELLEGRINO: Open Payments
NPI 1952889339 · MASSAPEQUA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$600 in 31 payments from 10 companies in 2025. Trend: 2023 $424 · 2024 $557 · 2025 $600
Food & beverage: $600
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $306 |
| Lundbeck LLC | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $33 |
| GENZYME CORPORATION | 1 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
Products named: VRAYLAR, QULIPTA, UBRELVY, REXULTI, GEMTESA, Veozah, AUSTEDO XR, DUPIXENT.
Industry payments across NY — which companies pay providers there.
